

REMARKS


Entry of this amendment is respectfully requested.

In this amendment, the specification is amended to include a Brief Description of the Drawings. Support for the amendment can be found in the specification (including figures) as originally filed. For example, Figures 1-6 are disclosed in the specification at page 8, lines 26-28. Figure 7 is disclosed at page 9, line 5. The correspondence between the sequence shown in Figure 8 and SEQ ID NO:12 is disclosed at page 5, lines 14-15. Figure 9 is described at page 64, line 12; and Figure 10 is described at page 64, line 18. No new matter is added.

In view of the above amendments and remarks, it is believed that the claims are in condition for allowance, and a determination to that effect is earnestly solicited.

Respectfully submitted,

Date: June 15, 1999



Reza Green, Reg. No. 38,475
• Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

s:\patent\4394214\pamd2

B